Business Context and Reporting Period
This Form 8-K Current Report was filed by Iridex Corporation on April 23, 2019. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance data.
Material Changes
- Board Expansion: The size of the Board of Directors was increased from seven to eight members effective April 23, 2019.
- Director Appointment: Scott Shuda was appointed to the Board of Directors.
Management Commentary, Risks, and Unusual Items
Compensatory Arrangements
In connection with his appointment, Mr. Shuda will receive:
- Standard compensation available to non-employee members of the Board and its committees.
- An option to purchase 15,000 shares of the Company's common stock.
- The stock options vest in equal monthly installments over four years following the grant date.
- Mr. Shuda is expected to execute the Company's standard form of indemnification agreement.
Director Background
Mr. Shuda brings extensive experience in the medical devices industry, including over 20 years in law, technology, and entrepreneurial endeavors. He previously served on Iridex's Board from December 2012 to April 2017. He is currently a Managing Director and Co-founder of Meridian OHC Partners, LP and BlueLine Partners, LLC, and serves as Chairman of the Board of InfuSystem Holdings, Inc.
Risks and Contingencies
The filing states there are no arrangements or understandings between Mr. Shuda and any other person regarding his election, no family relationships with other directors or officers, and no other transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 15,000 stock options granted to Scott Shuda.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Confirm the total number of outstanding shares and the impact of new option grants on dilution.
- Check for any subsequent filings regarding Mr. Shuda's committee assignments.